Bris­tol My­ers notch­es di­ver­si­ty gains af­ter re­vamp­ing its clin­i­cal tri­al lo­ca­tion strat­e­gy

Bris­tol My­ers Squibb is tak­ing its clin­i­cal tri­als to where di­verse pop­u­la­tions of peo­ple live and work to help boost di­ver­si­ty in its stud­ies. Its ini­tial goal at the be­gin­ning of 2020 was to lo­cate one-fourth of its US tri­al sites in di­verse ar­eas with­in five years, but BMS more than dou­bled that in less than two years.

Its lat­est ESG re­port, pub­lished in Au­gust, high­light­ed 58% of tri­al sites in di­verse ar­eas, but the com­pa­ny cur­rent­ly puts that num­ber even high­er at 62%, said Mokash Shar­ma, BMS’ head of glob­al de­vel­op­ment op­er­a­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER